New drug HRS-3095 aims to soothe stubborn hives

NCT ID NCT07613866

Not yet recruiting Symptom relief Sponsor: Chengdu Suncadia Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests whether the experimental drug HRS-3095 can reduce itching and wheals in adults with chronic spontaneous urticaria (hives) that isn't well controlled by antihistamines. About 190 participants will receive either the drug or a placebo daily for 4 weeks. The main goal is to see if the drug improves hive activity scores compared to placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS-3095 tablet
What this could lead to: If it works, this could point toward a new daily pill to better control chronic hives for people who don't get enough relief from antihistamines.
What could go wrong: This is an early Phase 2 trial with only 190 participants, so results may not apply to everyone. The drug may not prove more effective than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic idiopathic urticaria Chronic Urticaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC SPONTANEOUS URTICARIA

Contacts and locations

Locations

Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University

Hangzhou, Zhejiang, 310006, China
Huashan Hospital Affiliated to Fudan University

Shanghai, Shanghai Municipality, 200040, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.